新秀麗(01910.HK)出售保護殼業務 作價3,600萬美元
新秀麗(01910.HK)公布,向Telementum Global, LLC出售個人電子設備纖薄保護殼設計及分銷公司Speck,總現金代價為3,600萬美元,已於出售事項完成時同日支付,相關代價可就淨債項及營運資金作出慣常調整。
根據協議,若Speck截至今年底止年度的銷售淨額高於1.07億美元,則須額外支付或然400萬美元。Samsonite IP Holdings亦已向Speck轉讓Samsonite IP Holdings所持有並於Speck業務中使用的所有知識產權。
公司表示,,出售事項可讓公司集中資源以繼續發展其核心業務,出售事項的所得款項淨額將用作償還循環信貸融通下的部分未償還借款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.